SCHEMBL277537

SCHEMBL277537

CCCCCCC(CCC)NC=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 3/20 0.62
ADH1C P00326 3/20 0.62
ADH1A P07327 3/20 0.62
ADH7 P40394 3/20 0.62
ADH4 P08319 2/20 0.62
EPHX1 P07099 2/20 0.45
MAPT P10636 2/20 0.39
TSHR P16473 1/20 0.38
TRPA1 O75762 1/20 0.37
DDAH1 O94760 1/20 0.37
GAPDH P04406 1/20 0.37
GPR84 Q9NQS5 3/20 0.36
FDPS P14324 3/20 0.36
FFAR1 O14842 1/20 0.36
ZDHHC7 Q9NXF8 1/20 0.36
LMNA P02545 1/20 0.35
LCK P06239 1/20 0.35
PPARD Q03181 1/20 0.35
ZDHHC20 Q5W0Z9 1/20 0.35
ZDHHC2 Q9UIJ5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6022099 1.00 ADH1B (0.62) ADH1BADH1CADH1AADH7ADH4
SCHEMBL10580815 1.00 ADH1B (0.62) ADH1BADH1CADH1AADH7ADH4
SCHEMBL11111750 0.96 ADH1B (0.67) ADH1BADH1CADH1AADH7ADH4
SCHEMBL18558683 0.96 ADH1B (0.67) ADH1BADH1CADH1AADH7ADH4
SCHEMBL20835080 0.96 ADH1B (0.67) ADH1BADH1CADH1AADH7ADH4
SCHEMBL25693408 0.96 ADH1B (0.67) ADH1BADH1CADH1AADH7ADH4
SCHEMBL11110933 0.94 ADH1B (0.64) ADH1BADH1CADH1AADH7ADH4
SCHEMBL11435239 0.94 ADH1B (0.64) ADH1BADH1CADH1AADH7ADH4
SCHEMBL11450788 0.94 ADH1B (0.63) ADH1BADH1CADH1AADH7ADH4
SCHEMBL28824011 0.91 ADH1B (0.50) ADH1BADH1CADH1AADH7ADH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4844717-A KETONE AND AMIDE UNION OIL COMPANY OF CALIFORNIA (US) 1989-07-04 US claimed
US-4743273-A AMIDE AND KETONE, ANTIDEPOSIT AGENTS UNION OIL COMPANY OF CALIFORNIA (US) 1988-05-10 US claimed
EP-2439204-B1 HETEROCYCLIC COMPOUND AND HEMATOPOIETIC STEM CELL AMPLIFIER NISSAN CHEMICAL IND LTD (JP) 2017-01-04 EP disclosed
US-9527828-B2 Method for expanding hematopoietic stem cells using heterocyclic compound NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2016-12-27 US disclosed
EP-2218716-B1 METHOD FOR AMPLIFYING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND NISSAN CHEMICAL IND LTD (JP) 2016-11-16 EP disclosed
US-9328085-B2 Heterocyclic compounds and expansion agents for hematopoietic stem cells NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2016-05-03 US disclosed
US-20140227780-A1 METHOD FOR PRODUCING MEGAKARYOCYTES AND/OR PLATELETS FROM PLURIPOTENT STEM CELLS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2014-08-14 US disclosed
EP-2765187-A1 METHOD FOR PRODUCING MEGAKARYOCYTES AND/OR PLATELETS FROM PLURIPOTENT STEM CELLS Nissan Chemical Industries, Ltd. (JP) 2014-08-13 EP disclosed
US-8552031-B2 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-10-08 US disclosed
US-20130245255-A1 HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-09-19 US disclosed
US-20120128640-A1 HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS NISSAN CHEMICAL INDUSTRIES LTD. (JP) 2012-05-24 US disclosed
EP-1947101-A1 HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2008-07-23 EP disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed
EP-1819692-A1 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS Nissan Chemical Industries, Ltd. (JP) 2007-08-22 EP disclosed
EP-1490328-A4 COMPOSITIONS AND METHODS FOR INHIBITION OF PHOSPHOLIPASE A2 MEDIATED INFLAMMATION UNIV CALIFORNIA (US) 2007-08-15 EP disclosed
WO-2006062240-A1 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2006-06-15 WO disclosed
EP-1490328-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF PHOSPHOLIPASE A2 MEDIATED INFLAMMATION The Regents of The University of California (US) 2004-12-29 EP disclosed
WO-2003076389-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF PHOSPHOLIPASE A2 MEDIATED INFLAMMATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2003-09-18 WO disclosed
US-4844717-A KETONE AND AMIDE UNION OIL COMPANY OF CALIFORNIA (US) 1989-07-04 US disclosed
US-4217111-A REDUCING OCTANE REQUIREMENT CHEVRON RESEARCH COMPANY (US) 1980-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245255-A1 HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS HCLS1, RUNX1, RCC1 ADH1B 214/4885ADH1C 249/4885ADH1A 149/4885
US-20120128640-A1 HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS HCLS1, RUNX1, RCC1 ADH1B 214/4885ADH1C 249/4885ADH1A 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.